<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692376</url>
  </required_header>
  <id_info>
    <org_study_id>MSC-cGVHD-2020</org_study_id>
    <nct_id>NCT04692376</nct_id>
  </id_info>
  <brief_title>MSC for Treatment of cGVHD After Allo-HSCT</brief_title>
  <official_title>Mesenchymal Stem Cell for Treatment of Chronic Graft-versus-host Disease After Allogenetic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital, Army Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of mesenchymal stem cells in patients&#xD;
      with chronic graft-versus-host disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation(allo-HSCT) can cure many hematologic&#xD;
      diseases. Although great progress has been made in the prevention and treatment of side&#xD;
      effects associated with transplantation,chronic graft-versus-host disease(cGVHD) remains an&#xD;
      important complication that occurs in about 50% patients. The mortality of cGVHD and its&#xD;
      complication could reach up to 50%,and cGVHD seriously influence the quality of life. At&#xD;
      present, the first line treatment of cGVHD remains in discussion.&#xD;
&#xD;
      Mesenchymal stem cells (MSCs) are a form of multipotent adult stem cells that can be isolated&#xD;
      from bone marrow (BM), adipose tissue, and cord blood. Clinical applications of human MSCs&#xD;
      are evolving rapidly with goals of improving hematopoietic engraftment, preventing and&#xD;
      treating GVHD after allo-HSCT and so on. However, the efficacy of treatment of cGVHD remains&#xD;
      undetermined.&#xD;
&#xD;
      In the present study, the investigators will prospectively evaluate the efficacy and safety&#xD;
      of ex-vivo-expanded MSCs in treating patients with cGVHD.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 10, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>12 weeks after the first dose of MSCs</time_frame>
    <description>Overall response rate （ORR）includes complete response (CR) and part response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year after the first dose of MSCs</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DFS</measure>
    <time_frame>1 year after the first dose of MSCs</time_frame>
    <description>Disease-free survival (DFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 weeks after the first dose of MSCs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EBV DNA-emia</measure>
    <time_frame>1 year after the first dose of MSCs</time_frame>
    <description>EBV DNA-emia refers to detection of EBV DNA in peripheral blood via PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMV DNA-emia</measure>
    <time_frame>1 year after the first dose of MSCs</time_frame>
    <description>CMV DNA-emia refers to detection of CMV DNA in peripheral blood via PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGF</measure>
    <time_frame>1 year after the first dose of MSCs</time_frame>
    <description>Poor graft function (PGF) refers to a slow or incomplete recovery of blood cell counts (ANC ≤0.5x10^9/L and PLT ≤20x10^9/L) by +28 days after allo-HSCT or a fall in blood cell counts to levels fulfilling the diagnostic criteria for PGF after successful and prompt hematopoietic engraftment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">152</enrollment>
  <condition>Chronic Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>MSCs group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSCs group refers to treatment with mesenchymal stem cells (1×10^6 cells/kg, intravenously) weekly for 8 doses. Besides, glucocorticoids and cyclosporine (CsA) will be used for treatment concurrently.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoids and CsA will be used for treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal stem cells (MSCs) will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) weekly. MSCs will be administrated for 8 doses.</description>
    <arm_group_label>MSCs group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Glucocorticoids (i.e. Methylprednisolone) will be used with an initial dose of 1mg/kg.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>MSCs group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Cyclosporine (CsA) will be used with an initial dose of 2.5mg/kg/d and adjusted according to the concentration of CsA. The targeted concentration is 200-300 ng/Ml.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>MSCs group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A patient age of 18-65 years&#xD;
&#xD;
          -  Recipients of allogeneic hematopoietic stem cell transplantation Patients with&#xD;
             moderate/ severe cGVHD without systemic treatment&#xD;
&#xD;
          -  Subjects (or their legally acceptable representatives) must have signed an informed&#xD;
             consent document indicating that they understand the purpose of and procedures&#xD;
             required for the study and are willing to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood&#xD;
             pressure)&#xD;
&#xD;
          -  Primary disease relapse&#xD;
&#xD;
          -  Expected lifetime less than 3 months&#xD;
&#xD;
          -  Patients with any conditions not suitable for the trial (investigators' decision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qi-fa Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ren Lin, MD</last_name>
    <phone>+86-020-62787883</phone>
    <email>lansinglinren@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Hematology,Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ren Lin, MD</last_name>
      <phone>+86-020-61641613</phone>
      <email>lansinglinren@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qifa Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 26, 2020</study_first_submitted>
  <study_first_submitted_qc>December 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 29, 2020</last_update_submitted>
  <last_update_submitted_qc>December 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Qifa Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Chronic Graft-versus-host disease</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

